Immatics (NASDAQ:IMTX) Shares Down 4%

Immatics (NASDAQ:IMTX – Get Rating) traded down 4% during mid-day trading on Monday . The stock traded as low as $8.30 and last traded at $8.36. 155,528 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 197,931 shares. The stock had previously closed at $8.71.

Immatics Trading Down 0.2 %

The company’s 50-day simple moving average is $9.46 and its 200-day simple moving average is $10.39. The stock has a market capitalization of $631.95 million, a price-to-earnings ratio of 12.37 and a beta of 0.52.

Immatics (NASDAQ:IMTX – Get Rating) last announced its quarterly earnings results on Thursday, November 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Immatics had a net margin of 24.60% and a return on equity of 40.49%. The business had revenue of $15.18 million during the quarter, compared to analyst estimates of $13.36 million. On average, equities research analysts expect that Immatics will post 0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immatics

Several large investors have recently modified their holdings of IMTX. Millennium Management LLC increased its position in shares of Immatics by 1,414.3% during the second quarter. Millennium Management LLC now owns 566,752 shares of the company’s stock worth $4,936,000 after buying an additional 529,325 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Immatics during the third quarter worth $2,437,000. Point72 Asset Management L.P. acquired a new stake in shares of Immatics during the third quarter worth $2,306,000. Nantahala Capital Management LLC increased its position in shares of Immatics by 6.0% during the second quarter. Nantahala Capital Management LLC now owns 3,121,759 shares of the company’s stock worth $27,191,000 after buying an additional 177,100 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Immatics by 150.5% during the first quarter. JPMorgan Chase & Co. now owns 202,640 shares of the company’s stock worth $1,619,000 after buying an additional 121,754 shares during the period. 29.05% of the stock is currently owned by institutional investors and hedge funds.

About Immatics

(Get Rating)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.